Dynavax to Present at Bear Stearns Biotech West Coast Confab
BERKELEY, Calif., March 20 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced that Dino Dina, MD, President and CEO, will present an overview of the company at the Bear Stearns Biotech West Coast Confab at the Fairmont Hotel in San Francisco.
Dr. Dina's presentation will be webcast live at 11:00 am PT on Thursday, March 23, 2006. The webcast presentation may be accessed by visiting: http://customer.talkpoint.com/BEAR002/032306a_cy/linkdefault.asp?entity=dynava x .
The presentation may also be accessed by visiting the Dynavax website at http://www.Dynavax.com under the Investors section where it will also be archived for 30 days following the presentation.
About Dynavax
Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Dynavax's pipeline includes: TOLAMBA™, a ragweed allergy immunotherapeutic, that has completed a large-scale Phase 2/3 clinical trial, and is in a supportive clinical trial in ragweed allergic children; HEPLISAV™, a hepatitis B vaccine that is currently in a pivotal Phase 3 clinical trial; a cancer therapy currently in a Phase 2 clinical trial; and an asthma immunotherapeutic that has shown preliminary safety and pharmacology in a Phase 2a clinical trial.
SOURCE Dynavax Technologies Corporation
03/20/2006
CONTACT: Jane M. Green, PhD, Vice President, Corporate Communications of
Dynavax Technologies Corporation, +1-510-665-4630, or jgreen@dvax.com
Web site: http://www.dynavax.com
(DVAX)
03/20/2006 16:00 EST http://www.prnewswire.com